Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Paclitaxel plus carboplatin|DRUG: Paclitaxel and epirubicin
Sponsor: Chinese Academy of Medical Sciences